# Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity
> Note: PeptIQ is not a medical provider. Survodutide is an investigational dual agonist. Doses below reflect published trial designs — not a consumer protocol.
Survodutide (BI 456906) is a once-weekly glucagon receptor / GLP-1 receptor dual agonist. If retatrutide made people search "triple agonist dosing," survodutide is the dual-agonist cousin with a growing Phase 3 footprint — including SYNCHRONIZE obesity readouts.
Quick Answer: Survodutide Dosage
| Program | Weekly SC doses studied |
|---|---|
| Phase 2 dose-finding (46 weeks) | 0.6, 2.4, 3.6, 4.8 mg (plus placebo) |
| Phase 3 SYNCHRONIZE-1 (76 weeks) | Dose adjusted up to 3.6 mg or 6.0 mg vs placebo |
Route: subcutaneous, once weekly, with a formal dose-escalation period before maintenance.
Phase 2: What the Dose-Finding Trial Showed
In the Lancet Diabetes & Endocrinology Phase 2 obesity trial (no diabetes), participants escalated over ~20 weeks then maintained through week 46.
Approximate mean weight change at week 46 (planned treatment analysis):
| Weekly dose | Approx. mean weight change |
|---|---|
| 0.6 mg | ~−6% |
| 2.4 mg | ~−12.5% |
| 3.6 mg | ~−13% |
| 4.8 mg | ~−15% |
| Placebo | ~−3% |
GI adverse events were common — the same class pattern as other incretin / glucagon dual agonists. Escalation length matters.
Phase 3: SYNCHRONIZE-1 Dosing Context
SYNCHRONIZE-1 randomized adults with obesity (or overweight + comorbidity, excluding diabetes) to weekly survodutide adjusted up to 3.6 mg or 6.0 mg, or placebo, for 76 weeks.
Public treatment-regimen estimand results at week 76:
| Arm | Mean weight change |
|---|---|
| Up to 3.6 mg | ~−12.2% |
| Up to 6.0 mg | ~−13.0% |
| Placebo | ~−5.4% |
Efficacy estimands (modeling full adherence) were higher (mid-teens % range in public summaries). Liver-fat and visceral-fat substudy signals are part of why glucagon activity is interesting beyond the scale.
Titration Logic (Educational)
Dual agonists with glucagon activity are not "start at the top dose" drugs.
Typical trial pattern:
- Start low
- Step up on a fixed schedule (often over many weeks)
- Only hold/reduce for tolerability per protocol
- Spend the majority of the trial at maintenance
If you are comparing to retatrutide community titration charts, remember: survodutide milligrams are not retatrutide milligrams.
Survodutide vs Retatrutide vs Tirzepatide (Dosing Mental Model)
| Drug | Receptor story | Dosing vibe |
|---|---|---|
| Tirzepatide | GLP-1 + GIP | Approved weekly titration ladders |
| Survodutide | GLP-1 + glucagon | Investigational weekly dual agonist |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational weekly triple agonist |
Glucagon is why people talk about energy expenditure and liver fat — and why GI titration discipline still matters.
What to Track
- Weekly dose step and date
- Nausea / vomiting / constipation scores
- Protein intake and lifting
- Average weight + waist
- Optional: liver enzymes / imaging if clinically ordered (MASLD interest)
FAQ
Q: What is the usual survodutide dose?
A: There is no approved consumer dose. Phase 3 obesity arms targeted maintenance up to 3.6 mg or 6.0 mg weekly after escalation.
Q: Is survodutide daily?
A: No — once weekly in the obesity programs described here.
Q: Is 6 mg better than 3.6 mg?
A: In SYNCHRONIZE-1 public averages, 6.0 mg was modestly higher on mean weight loss under the treatment-regimen estimand; tolerability and individual response still dominate decisions in any future labeled use.
Q: Can I run survodutide with retatrutide?
A: Do not stack investigational multi-agonists casually. Overlapping pathways raise safety and attribution problems.
Bottom Line
Survodutide dosing in public science lands on weekly SC escalation toward the mid-single-digit milligram range, with Phase 2 exploring up to 4.8 mg and Phase 3 focusing on 3.6 mg and 6.0 mg maintenance targets. Treat those numbers as trial literacy for a hot dual agonist — not a DIY chart.
Download PeptIQ to log weekly dual-agonist style protocols cleanly.
Educational content only. Not medical advice.
